National Cancer Registry

National Cancer Registry (NCR)

Definition	A cancer registry is defined as a location, be it an office or institution, where collection, storage, analysis and interpretation of data on cancer patients take place (Jenson et al, 1991).
Objectives	- To measure cancer incidence - To describe cancer by time, place, persons and disease - To provide a national database for further epidemiological research
Case definition	Target cases are: - Incident cases by year of diagnosis - Malignant tumors confirmed by histopathology and/or hematology findings - Cancers of all sites
Sources of data	Data are collected through two main channels: the capture system (passive reporting) and the recapture system (active reporting). 1) The capture system: The capture system is based on physician’s routine reporting of cancer cases. Physician’s complete and send forms: - Directly from their clinic; or - Indirectly through the MOPH Drug Dispensing Center (DDC), where anti-cancer drugs are distributed to eligible patients 2) The recapture system: The recapture system is based on gathering information directly from histopathological and hematological laboratories. Data are collected in various ways, using hard or soft copies, or using database file or individual laboratory results depending on laboratories resources. This process is active since the NCR personnel actually contact the sites to obtain the necessary data. The recapture system validates and complements the capture approach.
Medical coding	The coding of cancer primary sites and cancer morphology is done using International Classification of Diseases for Oncology, third edition (ICD-O-3). The code includes information on the topography (primary site), the histology, the behavior and the grade of the tumor. The structure is C##.# M####/##, where: - C##.# specifies the primary site - M#### specifies the histology - /## specifies the behavior and the grade of the tumor
Reporting form	NCR reporting form

...

190

All

ATC	Name	B/G	Ingredients	Dosage	Form	Price
B05CX01	DEXTROSE 5% INJECTION, USP	G	Glucose - 5%	5%	Injectable solution	171,228 L.L
J06BB04	IMMUNOGLOBULINE HUMAINE DE L'HEPATITE B LFB	BioHuman	Hepatitis B immunoglobulin (human) - 500UI/5ml	500UI/5ml	Injectable solution	26,599,935 L.L
A10BX16	MOUNJARO KWIKPEN	B	Tirzepatide - 15mg/dose	15mg/dose	Injectable solution	39,601,065 L.L
B05CX01	DEXTROSE 5% INJECTION, USP	G	Glucose - 5%	5%	Injectable solution	158,587 L.L
N01AX03	KETAMINE PANPHARMA	G	Ketamine HCl - 250mg/5ml	250mg/5ml	Injectable solution	1,534,668 L.L
V03AB14	PROSULF 1%	B	Protamine sulfate - 50mg/5ml	1%	Injectable solution	8,216,459 L.L
B05CX01	DEXTROSE INJECTION 5%	G	Dextrose, H2O - 5g/100ml		Injectable solution	212,797 L.L
J06BD01	SYNAGIS	BioTech	Palivizumab - 100mg/ml	100mg/ml	Injectable solution	57,429,464 L.L
V03AB35	BRIDION	B	Sugammadex - 200mg/2ml	100mg/ml	Injectable solution	54,230,830 L.L
B05CX01	SERUFLEX DEXTROSE 5% INJECTION USP	G	Glucose - 5%	5%	Injectable solution	171,228 L.L
J06BD01	SYNAGIS	BioTech	Palivizumab - 50mg/0.5ml	50mg/0.5ml	Injectable solution	38,316,693 L.L
V03AB35	PLIBADEX	G	Sugammadex - 200mg/2ml	200mg/2ml	Injectable solution	47,914,365 L.L
B05CX01	SERUFLEX DEXTROSE 5% INJECTION USP	G	Glucose - 5%	5%	Injectable solution	158,587 L.L
V03AB35	RELANCIUM	G	Sugammadex - 100mg/ml	100mg/ml	Injectable solution	45,660,028 L.L
B05CX01	SERUFLEX DEXTROSE 5% INJECTION, USP	G	Glucose - 5%	5%	Injectable solution	171,228 L.L
J07AH08	MENACTRA MENINGOCOCCAL POLYSACCHARIDE DIPHTERIA TOXOID CONJUGATE VACCINE	B	Meningococcal Polysaccharides (serogroups A, C, Y and W-135) - 4mcg/0.5ml each, Diphteria Toxoid Protein - 48mcg/0.5ml		Injectable solution	6,144,048 L.L
N01BB01	BUPIVACAINE AGUETTANT for spinal anaesthesia	G	Bupivacaine HCl - 20mg/4ml	20mg/4ml	Injectable solution	1,554,826 L.L
V03AB35	? SUGAMMADEX	G	Sugammadex - 200mg/2ml	100mg/ml	Injectable solution	5,214,109 L.L
B05CX01	SERUFLEX DEXTROSE 5% INJECTION, USP	G	Glucose - 5%	5%	Injectable solution	193,062 L.L
N01BB01	BUPIVACAINE HEAVY PANPHARMA	G	Bupivacaine HCl - 20mg/4ml	20mg/4ml	Injectable solution	2,586,897 L.L
V03AB35	PLIBADEX	G	Sugammadex - 500mg/5ml	500mg/5ml	Injectable solution	98,646,620 L.L
B05CX01	SOLUFLEX DEXTROSE 5% INJECTION USP	G	Glucose - 5%	5%	Injectable solution	186,167 L.L
J07AH08	MENQUADFI	G	Meningococcal (serogroups A, C, W and Y) conjugate vaccine -		Injectable solution	4,859,334 L.L
N01BB01	BUPIVACAINE AGUETTANT 2.5MG/ML	G	Bupivacaine HCl - 50mg/20ml	50mg/20ml	Injectable solution	2,736,063 L.L
B05CX01	SOLUFLEX DEXTROSE 5% INJECTION USP	G	Glucose - 5%	5%	Injectable solution	186,167 L.L
J01MA02	CIPROFLOXACINE PANPHARMA	G	Ciprofloxacine (HCl) - 200mg/100ml	200mg/100ml	Injectable solution	5,120,040 L.L
N01BB01	BUPIVACAINE AGUETTANT 5MG/ML	G	Bupivacaine HCl - 100mg/20ml	100mg/20ml	Injectable solution	3,078,743 L.L
B05CX01	SOLUFLEX DEXTROSE 5% INJECTION, USP	G	Glucose - 5%	5%	Injectable solution	205,703 L.L
J01MA02	CIPROFLOXACINE PANPHARMA	G	Ciprofloxacine (HCl) - 200mg/100ml	200mg/100ml	Injectable solution	5,120,040 L.L
J07AL01	PNEUMOVAX 23	B	Polysaccharides from each of 23 capsular types of Streptococcus pneumoniae - 25mcgx23serotypes/0.5ml		Injectable solution	2,378,601 L.L

...

190